坦桑尼亚三阴性与非三阴性乳腺癌患者临床病理特征及生存率的比较

IF 4.2 2区 医学 Q1 ONCOLOGY
Oncologist Pub Date : 2025-10-17 DOI:10.1093/oncolo/oyaf345
Eulade Rugengamanzi, Nazima Dharsee, Emmanuel L Lugina, Jesse Jonathan Kashabano, Gad Murenzi, Alan Paciorek, Godfrey Malangwa, Mathias Banzi, Glory Makupa, Godwin Nnko, Leila Mwakipunda, Amie Y Lee
{"title":"坦桑尼亚三阴性与非三阴性乳腺癌患者临床病理特征及生存率的比较","authors":"Eulade Rugengamanzi, Nazima Dharsee, Emmanuel L Lugina, Jesse Jonathan Kashabano, Gad Murenzi, Alan Paciorek, Godfrey Malangwa, Mathias Banzi, Glory Makupa, Godwin Nnko, Leila Mwakipunda, Amie Y Lee","doi":"10.1093/oncolo/oyaf345","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is a heterogeneous disease with a wide spectrum of subtypes, each with distinct biological features. Data on tumor subtypes in East Africa is sparse despite the rising incidence of breast cancer in this region. We aimed to determine the prevalence of triple-negative breast cancer (TNBC) and to compare clinicopathological features, overall survival (OS), and factors affecting OS of patients with TNBC and non-TNBC in Tanzania.</p><p><strong>Patients and methods: </strong>This retrospective nested case-control study included patients with histologically proven breast cancer treated at Ocean Road Cancer Institute (ORCI) in Tanzania from January 2018 to December 2019. Logistic regression was used to determine factors associated with TNBC, and Cox proportional hazards regression was used to determine the factors independently associated with overall survival.</p><p><strong>Results: </strong>TNBC constituted 23.3% of all breast cancer diagnoses. Patients in the TNBC group were younger (median age 46 vs 53 years p < 0.001) and more often presented with stage IV disease (12% vs 4%, p = 0.001). Three-year overall survival (OS) was significantly lower in the TNBC group (36%) compared to the non-TNBC group (57%) (p = 0.004) and remained lower for the TNBC group across every tumor stage. Brain metastasis was higher in the TNBC group (34% vs 7%, p < 0.001). Factors associated with improved survival included shorter symptom duration (0.53, (0.36-0.78), earlier stage (0.23, (0.12-0.46)), use of neoadjuvant chemotherapy (0.59 (0.40-0.86)), and surgery with clean margins (0.34 (0.19-0.60)).</p><p><strong>Conclusions: </strong>TNBC accounted for nearly a quarter of the breast cancers at ORCI. TNBC was associated with younger age, more aggressive clinicopathologic features, and worse survival. Efforts toward earlier diagnosis and optimized therapies will be critical to improving TNBC outcomes in Tanzania.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of Clinicopathological Features and Survival in Triple-Negative and Non-Triple Negative Breast Cancer Patients in Tanzania.\",\"authors\":\"Eulade Rugengamanzi, Nazima Dharsee, Emmanuel L Lugina, Jesse Jonathan Kashabano, Gad Murenzi, Alan Paciorek, Godfrey Malangwa, Mathias Banzi, Glory Makupa, Godwin Nnko, Leila Mwakipunda, Amie Y Lee\",\"doi\":\"10.1093/oncolo/oyaf345\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Breast cancer is a heterogeneous disease with a wide spectrum of subtypes, each with distinct biological features. Data on tumor subtypes in East Africa is sparse despite the rising incidence of breast cancer in this region. We aimed to determine the prevalence of triple-negative breast cancer (TNBC) and to compare clinicopathological features, overall survival (OS), and factors affecting OS of patients with TNBC and non-TNBC in Tanzania.</p><p><strong>Patients and methods: </strong>This retrospective nested case-control study included patients with histologically proven breast cancer treated at Ocean Road Cancer Institute (ORCI) in Tanzania from January 2018 to December 2019. Logistic regression was used to determine factors associated with TNBC, and Cox proportional hazards regression was used to determine the factors independently associated with overall survival.</p><p><strong>Results: </strong>TNBC constituted 23.3% of all breast cancer diagnoses. Patients in the TNBC group were younger (median age 46 vs 53 years p < 0.001) and more often presented with stage IV disease (12% vs 4%, p = 0.001). Three-year overall survival (OS) was significantly lower in the TNBC group (36%) compared to the non-TNBC group (57%) (p = 0.004) and remained lower for the TNBC group across every tumor stage. Brain metastasis was higher in the TNBC group (34% vs 7%, p < 0.001). Factors associated with improved survival included shorter symptom duration (0.53, (0.36-0.78), earlier stage (0.23, (0.12-0.46)), use of neoadjuvant chemotherapy (0.59 (0.40-0.86)), and surgery with clean margins (0.34 (0.19-0.60)).</p><p><strong>Conclusions: </strong>TNBC accounted for nearly a quarter of the breast cancers at ORCI. TNBC was associated with younger age, more aggressive clinicopathologic features, and worse survival. Efforts toward earlier diagnosis and optimized therapies will be critical to improving TNBC outcomes in Tanzania.</p>\",\"PeriodicalId\":54686,\"journal\":{\"name\":\"Oncologist\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-10-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncologist\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/oncolo/oyaf345\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyaf345","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:乳腺癌是一种异质性疾病,具有广泛的亚型,每种亚型都具有不同的生物学特征。尽管东非地区乳腺癌发病率不断上升,但该地区关于肿瘤亚型的数据很少。我们的目的是确定三阴性乳腺癌(TNBC)的患病率,并比较坦桑尼亚TNBC和非TNBC患者的临床病理特征、总生存期(OS)和影响OS的因素。患者和方法:本回顾性巢式病例对照研究纳入了2018年1月至2019年12月在坦桑尼亚海洋道路癌症研究所(ORCI)接受组织学证实的乳腺癌患者。采用Logistic回归确定与TNBC相关的因素,采用Cox比例风险回归确定与总生存率独立相关的因素。结果:三阴癌占所有乳腺癌诊断的23.3%。TNBC组患者更年轻(中位年龄为46岁vs 53岁)。结论:TNBC占ORCI乳腺癌患者的近四分之一。TNBC与更年轻、更具侵袭性的临床病理特征和更差的生存率相关。早期诊断和优化治疗的努力对于改善坦桑尼亚TNBC的预后至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comparison of Clinicopathological Features and Survival in Triple-Negative and Non-Triple Negative Breast Cancer Patients in Tanzania.

Purpose: Breast cancer is a heterogeneous disease with a wide spectrum of subtypes, each with distinct biological features. Data on tumor subtypes in East Africa is sparse despite the rising incidence of breast cancer in this region. We aimed to determine the prevalence of triple-negative breast cancer (TNBC) and to compare clinicopathological features, overall survival (OS), and factors affecting OS of patients with TNBC and non-TNBC in Tanzania.

Patients and methods: This retrospective nested case-control study included patients with histologically proven breast cancer treated at Ocean Road Cancer Institute (ORCI) in Tanzania from January 2018 to December 2019. Logistic regression was used to determine factors associated with TNBC, and Cox proportional hazards regression was used to determine the factors independently associated with overall survival.

Results: TNBC constituted 23.3% of all breast cancer diagnoses. Patients in the TNBC group were younger (median age 46 vs 53 years p < 0.001) and more often presented with stage IV disease (12% vs 4%, p = 0.001). Three-year overall survival (OS) was significantly lower in the TNBC group (36%) compared to the non-TNBC group (57%) (p = 0.004) and remained lower for the TNBC group across every tumor stage. Brain metastasis was higher in the TNBC group (34% vs 7%, p < 0.001). Factors associated with improved survival included shorter symptom duration (0.53, (0.36-0.78), earlier stage (0.23, (0.12-0.46)), use of neoadjuvant chemotherapy (0.59 (0.40-0.86)), and surgery with clean margins (0.34 (0.19-0.60)).

Conclusions: TNBC accounted for nearly a quarter of the breast cancers at ORCI. TNBC was associated with younger age, more aggressive clinicopathologic features, and worse survival. Efforts toward earlier diagnosis and optimized therapies will be critical to improving TNBC outcomes in Tanzania.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Oncologist
Oncologist 医学-肿瘤学
CiteScore
10.40
自引率
3.40%
发文量
309
审稿时长
3-8 weeks
期刊介绍: The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信